Phase I study of onapristone, a type I antiprogestin, in female patients with previously treated recurrent or metastatic progesterone receptor-expressing cancers.
Cottu, Paul H
Phase I study of onapristone, a type I antiprogestin, in female patients with previously treated recurrent or metastatic progesterone receptor-expressing cancers. [electronic resource] - PloS one 2018 - e0204973 p. digital
Publication Type: Clinical Trial, Phase I; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
1932-6203
10.1371/journal.pone.0204973 doi
Adult
Aged
Aged, 80 and over
Antineoplastic Agents--adverse effects
Biomarkers, Tumor--metabolism
Breast Neoplasms--drug therapy
Delayed-Action Preparations
Female
Gonanes--adverse effects
Half-Life
Humans
Middle Aged
Nausea--etiology
Neoplasm Metastasis
Neoplasm Recurrence, Local
Receptors, Progesterone--metabolism
Phase I study of onapristone, a type I antiprogestin, in female patients with previously treated recurrent or metastatic progesterone receptor-expressing cancers. [electronic resource] - PloS one 2018 - e0204973 p. digital
Publication Type: Clinical Trial, Phase I; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
1932-6203
10.1371/journal.pone.0204973 doi
Adult
Aged
Aged, 80 and over
Antineoplastic Agents--adverse effects
Biomarkers, Tumor--metabolism
Breast Neoplasms--drug therapy
Delayed-Action Preparations
Female
Gonanes--adverse effects
Half-Life
Humans
Middle Aged
Nausea--etiology
Neoplasm Metastasis
Neoplasm Recurrence, Local
Receptors, Progesterone--metabolism